Marie F. Breinholt

Copenhagen, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

TP53 Mutation Is the Only Robust Mutational Biomarker for Outcome Found in a Consecutive Clinical Cohort of Real-Word Patients With Primary Large B-Cell Lymphoma.

TP53 Mutation Is the Only Robust Mutational Biomarker for Outcome Found in a Consecutive Clinical Cohort of Real-Word Patients With Primary Large B-Cell Lymphoma.

Journal: European journal of haematology

Published: September 18, 2024

NOTCH1 Mutations Are Associated With Therapy-Resistance in Patients With B-Cell Lymphoma Treated With CD20xCD3 Bispecific Antibodies.

NOTCH1 Mutations Are Associated With Therapy-Resistance in Patients With B-Cell Lymphoma Treated With CD20xCD3 Bispecific Antibodies.

Journal: American journal of hematology

Published: July 30, 2024

Mutational heterogeneity in large B-cell lymphoma: insights from paired biopsies.

Mutational heterogeneity in large B-cell lymphoma: insights from paired biopsies.

Journal: Annals of hematology

Published: July 07, 2024

Localized large B-cell lymphoma with MYC and BCL6 rearrangements as an unexpected finding in an appendectomy specimen.

Localized large B-cell lymphoma with MYC and BCL6 rearrangements as an unexpected finding in an appendectomy specimen.

Journal: APMIS : acta pathologica, microbiologica, et immunologica Scandinavica

Published: March 22, 2024

Mutational landscape in Waldenström macroglobulinemia evaluated using a next-generation sequencing lymphoma panel in routine clinical practice.

Mutational landscape in Waldenström macroglobulinemia evaluated using a next-generation sequencing lymphoma panel in routine clinical practice.

Journal: Leukemia & lymphoma

Published: February 10, 2024

Multi-site pre-therapeutic biopsies demonstrate genetic heterogeneity in patients with newly diagnosed diffuse large B-cell lymphoma.

Multi-site pre-therapeutic biopsies demonstrate genetic heterogeneity in patients with newly diagnosed diffuse large B-cell lymphoma.

Journal: Leukemia & lymphoma

Published: June 17, 2023

Next generation sequencing in routine diagnostics of mature non-Hodgkin's B-cell lymphomas.

Next generation sequencing in routine diagnostics of mature non-Hodgkin's B-cell lymphomas.

Journal: European journal of haematology

Published: April 21, 2023

Inactivating BTK mutations in large B-cell lymphoma in a real-world cohort: Strong correlation with BCL2 translocation.

Inactivating BTK mutations in large B-cell lymphoma in a real-world cohort: Strong correlation with BCL2 translocation.

Journal: EJHaem

Published: April 29, 2022

The value of next-generation sequencing in routine diagnostics and management of patients with cytopenia.

The value of next-generation sequencing in routine diagnostics and management of patients with cytopenia.

Journal: International journal of laboratory hematology

Published: October 29, 2021

An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphoma.

An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphoma.

Journal: Oncoimmunology

Published: September 25, 2021

The clinical course and life expectancy of patients with multiple myeloma who discontinue their first daratumumab-containing line of therapy.

The clinical course and life expectancy of patients with multiple myeloma who discontinue their first daratumumab-containing line of therapy.

Journal: American journal of hematology

Published: September 10, 2021

Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients.

Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients.

Journal: Hematological oncology

Published: June 11, 2021

Showing 1-12 of 23

Last Updated: 09/26/2026